t
On 01 September 2026, Coiled Therapeutics plc announced the appointment of Shore Capital Stockbrokers Limited as a joint corporate broker. Shore Capital will act alongside the Company's existing nominated adviser and joint broker, SP Angel Corporate Finance LLP, and joint broker, CPS Capital Group Pty Ltd, with immediate effect.
| Date | 1 Sept 2026 |
| Time | 07:00:20 |
| Category | Corporate updates |
| ID | 6216S |
1 September 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Appointment of Joint Corporate Broker
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, is pleased to announce the appointment of Shore Capital Stockbrokers Limited ("Shore Capital") as a joint corporate broker with immediate effect.
Shore Capital will act alongside the Company's existing nominated adviser and joint broker, SP Angel Corporate Finance LLP, and joint broker, CPS Capital Group Pty Ltd.
For further information, please contact:
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO)
|
Via Burson Buchanan |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
|
+44 (0)20 3470 0470 |
|
|
|
|
|
|
Shore Capital Stockbrokers Limited (Joint Broker) David Coaten / Sophie Collins
|
+44 (0)20 7408 4090 |
|
|
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino |
+61 (0)8 9223 2222 |
|
|
|
|
|
|
Burson Buchanan (Public Relations) |
+44 (0)20 7466 5000 |
|
|
Henry Harrison Topham / Jamie Hooper / Toto Berger |
|
|
|
|
|
|
|
Harbor Access (US Investor Relations) |
+1 475 477 9404 |
|
|
Matt Kelly / Jonathan Paterson |
|
|
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in a Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy is designed to generate the clinical evidence sought by potential pharmaceutical partners in selected tumour types, including ovarian and prostate cancer, while advancing a broader pipeline that includes a STAT6 siRNA programme for immunology indications.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.
By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.
AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate Phase I/II dose-expansion cohorts in ovarian and prostate cancer in H2 2026.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.